[Korea Biomedical Review] How will election pledges affect drug reimbursement in Korea?

[Korea Biomedical Review] How will election pledges affect drug reimbursement in Korea?

How will election pledges affect drug reimbursement in Korea? Whether the NHIS grants insurance benefits for a specific drug, how and at what price has a profound effect on the medical practice of the pharmaceutical industry and patients suffering from particular diseases. Health insurance benefit determination procedure starts with a pharmaceutical company applying new drug listings to the Health Insurance Review and Assessment Service (HIRA). Next, the agency holds a meeting of the Drug Reimbu...

#PA #PublicAffairs #마콜컨설팅그룹 #이보형사장 #퍼블릭어페어즈

원문링크 : [Korea Biomedical Review] How will election pledges affect drug reimbursement in Korea?

 등록된 다른 글

[Korea Times] How Candlelight protests Impact Business Environment

[한국경제 인터뷰] “社측도 ‘주고받기식’ 벗어나야,,, 노조와 섬세한 소통 중요” - 마콜컨설팅그룹 사장 이보형

[매경럭스맨 칼럼] 시장 위의 “보이는 손(Visible hand)”과 경영전략 - 마콜컨설팅그룹 사장 이보형

[매경춘추] 인구절벽에 맞서자 - 마콜컨설팅그룹 사장 이보형

[매경춘추] 정책검증과 투명성 - 마콜컨설팅그룹 사장 이보형

옥스포드대학 데니스 노블(Denis Noble)교수 마콜컨설팅그룹 특강

[Korea Biomedical Review] Why regulatory reform makes little progress in Korea

[Korea Biomedical Review] The advent of an era with creative policy proposals